Open Beta
TREN
MetriLume
TREN

US marketsSTOK

SEC-sourced researchBeta

STOK

Stoke Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001623526
Exchange
Nasdaq
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Oct 2, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 36,555,000.0000 USD; December 2025: 184,420,000.0000 USD184.4M USD0 USD0December 2024December 2025
STOK · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202436,555,000.0000Mar 16, 2026
December 2025184,420,000.0000Mar 16, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025184,420,000.0000-6,885,000.000045,585,000.0000418,434,000.000065,977,000.0000Mar 16, 2026
December 202436,555,000.0000-88,981,000.0000-86,851,000.0000271,555,000.000042,534,000.0000Mar 16, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenues$184.42MDecember 2025Mar 16, 202610-K
Previous period revenueRevenues$36.56MDecember 2024Mar 16, 202610-K
Net incomeNetIncomeLoss-$6.89MDecember 2025Mar 16, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities$45.59MDecember 2025Mar 16, 202610-K
Total assetsAssets$418.43MDecember 2025Mar 16, 202610-K
Total liabilitiesLiabilities$65.98MDecember 2025Mar 16, 202610-K

New filings

Explore methodology ↗